UNSPSC 51142522: Dihydroergocryptine

This classification denotes an antiparkinson drug with the molecular formula C32H43N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67V3FSL2GL, chemically known as ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, but generally known as Dihydroergocryptine, which bears US NIH Compound Identifier 114948. European Medicines Agency schedules Dihydroergocryptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13588MIG.

World Health Organization schedules amantadine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROERGOCRYPTINE remains the US FDA Preferred Term for this commodity. SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.

UNSPSC 51142522 Dihydroergocryptine is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceuticals and related health products to government entities and health systems, though the recent solicitations tracked under this code show limited direct alignment with dihydroergocryptine specifically and instead capture broader pharmaceutical procurement, emergency response pharmaceuticals, and pharmacy benefit management initiatives. State and local procurement under this code spans health departments, county health systems, and state health and human services agencies, with issuing bodies including county governments managing public health functions and state-level cooperative purchasing alliances administering multi-jurisdictional pharmaceutical supply agreements. The scope of work includes the supply of pharmaceutical products (both brand and generic), over-the-counter items, and emergency-response medications such as naloxone, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and specified insurance and employment verification standards.

Recent activity appears concentrated in Florida and Minnesota, with secondary Texas-level market research. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to county health facilities, with responses due July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with proposals due March 26, 2026 and contract effectiveness July 1, 2026; and the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription fulfillment models for state pharmacy benefit programs. The Minnesota and Texas solicitations indicate state-level appetite for pharmaceutical supply consolidation and alternative distribution models, suggesting future formal procurement vehicles in those jurisdictions.